Yahoo Web Search

Search results

1. People also ask

   What happened to Australian Pharmaceutical Industries Limited (API)?

   • Wesfarmers acquired Australian Pharmaceutical Industries Limited (API) on 31 March 2022 by way of a scheme of arrangement. As a result, API shares were suspended from close of trading on the ASX on 22 March 2022 and it was delisted from the ASX on 1 April 2022.

   API Acquisition - Wesfarmers

   www.wesfarmers.com.au/investor-centre/your-shareholding/api-acquisition

   See all results for this question

   Who is Australian Pharmaceutical Industries (API)?

   • Australian Pharmaceutical Industries (API) | 17,028 followers on LinkedIn. Australian Pharmaceutical Industries Limited (API) is one of Australia’s leading pharmaceutical distributors and fastest growing health and beauty retailers. API is the parent company of Priceline Pharmacy, Soul Pattinson Chemist and Pharmacist Advice.

   Australian Pharmaceutical Industries (API) | LinkedIn

   au.linkedin.com/company/australian-pharmaceutical-industries

   See all results for this question

   What is Australian Pharmaceutical Industries?

   • Australian Pharmaceutical Industries was incorporated as Chemists' Co-operative of New South Wales Limited in 1910 and later became known as Wholesale Drug Co before adopting its current name, Australian Pharmaceutical Industries, in 1971.

   Australian Pharmaceutical Industries - Wikipedia

   en.wikipedia.org/wiki/Australian_Pharmaceutical_Industries

   See all results for this question

   Why did API buy hospital supplies of Australia?

   • On 29 October 2001, API purchased Hospital Supplies of Australia, the hospital and medical wholesale distribution business previously owned by the Victorian Healthcare Association. This enabled API to extend its distribution business to the public and private hospital market. [citation needed]

   Australian Pharmaceutical Industries - Wikipedia

   en.wikipedia.org/wiki/Australian_Pharmaceutical_Industries

   See all results for this question

2. en.wikipedia.org › wiki › Australian_PharmaceuticalAustralian Pharmaceutical Industries - Wikipedia

   en.wikipedia.org › wiki › Australian_Pharmaceutical

   • Cached

   Australian Pharmaceutical Industriea (API) is a health and beauty company owned by Wesfarmers. It is involved in pharmaceutical distribution, retailing and manufacturing. API is Australia's largest wholesale distributor of pharmaceutical and allied products. [1]

3. www.wesfarmers.com.au › investor-centre › yourAustralian Pharmaceutical Industries Acquisition - Wesfarmers

   www.wesfarmers.com.au › investor-centre › your

   • Cached

   Nov 8, 2021 · Wesfarmers acquired Australian Pharmaceutical Industries Limited (API) on 31 March 2022 by way of a scheme of arrangement. As a result, API shares were suspended from close of trading on the ASX on 22 March 2022 and it was delisted from the ASX on 1 April 2022.

4. au.linkedin.com › company › australianAustralian Pharmaceutical Industries (API) | LinkedIn

   au.linkedin.com › company › australian

   Australian Pharmaceutical Industries Limited (API) is one of Australia’s leading pharmaceutical distributors and fastest growing health and beauty retailers. API is the parent company of...

5. www.wesfarmers.com.au › util › news-mediaProposal to acquire Australian Pharmaceutical Industries

   www.wesfarmers.com.au › util › news-media

   • Cached

   Wesfarmers (ASX:WES) has submitted a non-binding, indicative offer to the Board of Australian Pharmaceutical Industries Limited (“API”, ASX:API) to acquire 100 per cent of API’s shares outstanding for $1.38 cash per share by way of a scheme of arrangement (“Proposal”).

6. Top Stories

   • 

     Simply Wall St. via Yahoo

     Are Investors Undervaluing Neuren Pharmaceuticals Limited (ASX:NEU) By 46%?

     2 days ago

   • 

     Simply Wall St. via Yahoo

     Three ASX Growth Companies With Insider Ownership Exceeding 12%

     2 hours ago

   • The Shelby County Reporter

     Small Business - Shelby County Reporter | Shelby County Reporter

     Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and ...

     3 days ago

   • Cordele Dispatch

     Small Business - Cordele Dispatch | Cordele Dispatch

     Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares ...

     17 hours ago

   • Simply Wall St. via Yahoo

     ASX Growth Leaders With High Insider Ownership In June 2024

     10 hours ago

   • Simply Wall St. via Yahoo

     June 2024 Insight Into ASX Growth Companies With High Insider Ownership

     2 days ago

   • StreetInsider

     Aurora Unveils Premium Resin Cartridges in Australia

     NASDAQ | TSX: ACB Canada's Leading Medical Cannabis Company and MedReleaf Australia Launch Innovative Resin Cartridges to Offer...

     18 hours ago

   View all

7. www.wesfarmers.com.au › our-businesses › wesfarmersWesfarmers Health

   www.wesfarmers.com.au › our-businesses › wesfarmers

   • Cached

   Australian Pharmaceutical Industries. Since its beginnings in 1910, API has grown from a small co-operative of three pharmacies to now one of Australia’s leading health, beauty and wellbeing companies.

8. finance.yahoo.com › news › investors-know-australianWhat Investors Should Know About Australian Pharmaceutical ...

   finance.yahoo.com › news › investors-know-australian

   • Cached

   Apr 18, 2019 · Australian Pharmaceutical Industries Limited (ASX:API) is a small-cap stock with a market capitalization of AU$749m. While investors primarily focus on the growth potential and competitive...

9. finance.yahoo.com › news › earnings-australianEarnings Update: Australian Pharmaceutical Industries Limited ...

   finance.yahoo.com › news › earnings-australian

   • Cached

   Apr 24, 2021 · Following last week's earnings report, Australian Pharmaceutical Industries' five analysts are forecasting 2021 revenues to be AU$4.04b, approximately in line with the last 12 months.